Friday, February 02, 2024 5:14:16 PM
meirluc,
The issue is the flow of positive news events. Obviously a partnership deal announced near or at the time of approval would make any attempt to manipulate very difficult to impossible. Approval without this news needs to be followed up with positive statements by the company about how they expect to bring income into the picture without delay. That requires them to project how much revenue will be available from immediately available UK set asides and or bring a NICE decision time line into play. They must also project what growth rate they expect based on initial expected demand from all comers and new trial plans and financing plan for them if an outright partnership is not announced. They can project a modest initial growth rate but need to project a strong build. I believe Linda has post approval moves covered but if not done properly this is where manipulation could continue after an initial surge.
I believe there is a very significant amount of news that can and will be shared that will help ward off manipulation after approval but if any opening is left for it you can be certain that opening will be taken especially if any hostile buyout offers are brought into the mix. Best wishes.
The issue is the flow of positive news events. Obviously a partnership deal announced near or at the time of approval would make any attempt to manipulate very difficult to impossible. Approval without this news needs to be followed up with positive statements by the company about how they expect to bring income into the picture without delay. That requires them to project how much revenue will be available from immediately available UK set asides and or bring a NICE decision time line into play. They must also project what growth rate they expect based on initial expected demand from all comers and new trial plans and financing plan for them if an outright partnership is not announced. They can project a modest initial growth rate but need to project a strong build. I believe Linda has post approval moves covered but if not done properly this is where manipulation could continue after an initial surge.
I believe there is a very significant amount of news that can and will be shared that will help ward off manipulation after approval but if any opening is left for it you can be certain that opening will be taken especially if any hostile buyout offers are brought into the mix. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
